Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples. - Wikidata - wikimedia - TriplyDB

Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.

Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.

http://www.wikidata.org/entity/Q34424018

about

GTSE1 expression represses apoptotic signaling and confers cisplatin resistance in gastric cancer cells.Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin Silencing GTSE-1 expression inhibits proliferation and invasion of hepatocellular carcinoma cells Nucleotide excision repair is a potential therapeutic target in multiple myeloma.The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.The DNA damage response activates HPV16 late gene expression at the level of RNA processing.

P2860

Q35712961-4B6BB32F-2867-4A81-9608-A295CF59CB62 Q36432104-396A42F2-03A7-4810-B64E-FFE8E761814C Q37096099-5F81B763-D672-4A39-9653-8B2C096B59C7 Q38739689-73647C4E-D1A1-4560-AA0B-2E0E30560B27 Q46386898-ADBAC61D-0230-415D-B715-E0572E52F8B4 Q55439768-E8DE233C-5A1F-49F3-A6FD-4B6975E50E84

P2860

Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.

http://www.wikidata.org/entity/Q34424018

description

2012 nî lūn-bûn

@nan

2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

Evidence for different mechani ...... ired resistant tumour samples.

@ast

Evidence for different mechani ...... ired resistant tumour samples.

@en

Evidence for different mechani ...... ired resistant tumour samples.

@nl

type

label

Evidence for different mechani ...... ired resistant tumour samples.

@ast

Evidence for different mechani ...... ired resistant tumour samples.

@en

Evidence for different mechani ...... ired resistant tumour samples.

@nl

prefLabel

Evidence for different mechani ...... ired resistant tumour samples.

@ast

Evidence for different mechani ...... ired resistant tumour samples.

@en

Evidence for different mechani ...... ired resistant tumour samples.

@nl

P1433

Q34424018-9C38F550-9BDE-4D9C-885F-51DCB521116F

P1476

Q34424018-DD7B96C7-2D5C-490C-A9AD-B2AB29E1A6D9

P2093

Q34424018-18084730-DDE7-4549-BA0B-4E5D8085FA20

Q34424018-18B1F648-CA19-42BB-944A-CC445A802DF4

Q34424018-1F3DFBC0-6E35-49D7-A959-B3FD37B8D6B0

Q34424018-5331AFB7-D1C0-40FA-A770-9E2136ED2E15

Q34424018-729EC044-110F-4BEF-A72E-278F61A7EFDE

Q34424018-8F6CEA17-5E62-408F-8EC2-28333B3E3C8F

Q34424018-B181206B-561C-483D-8D5D-AAD83591D275

Q34424018-B3E1CFDF-650A-496A-8686-907B56ECE887

Q34424018-EF5A9D98-C342-4CD7-95F3-37BE34E2CE70

P2860

Q34424018-00E290E2-4D75-4762-98C1-838DFAB51BC2

Q34424018-01FF475D-5B26-46C5-846B-1BD0B76D0F19

Q34424018-1D8DE65D-783A-40D3-AF8C-D05C59B17F7E

Q34424018-1E677693-D940-4B32-9D83-4A5FE1DF6A53

Q34424018-1F667A6E-D850-450F-85B2-55B448B690E1

Q34424018-28AAF9B5-B32F-4953-9D5E-E8B1234934A5

Q34424018-2DFA3A6E-5978-4778-9E44-ECF2610E4F70

Q34424018-3E3591CC-6A29-4985-9DC6-F25748146923

Q34424018-58E5ACF8-DBEB-4C76-8583-626BB0175091

Q34424018-64B9EF43-5067-45D0-A431-A9A2A4C1F966

P2888

Q34424018-E8D51831-3B91-426C-B989-008A59D612F3

P304

Q34424018-C79BEF8F-8A77-44D6-B8A7-CD37C0BD05EA

P31

Q34424018-030FCC59-494B-4D6C-9373-008D5B3EDA33

P356

Q34424018-DC11B9B9-1957-4EF2-81DE-2865594CC446

P407

Q34424018-286B9E87-B024-447B-B3E6-A8000A4B9445

P478

Q34424018-53C0E2DB-80B8-4977-9858-3F3728794527

P50

Q34424018-B7D17230-96C7-4EFC-9E1F-92E88FB58ED8

P577

Q34424018-E19D7BA7-6BD8-4C92-832A-CCB26BF1EC57

P5875

Q34424018-A0BED6D9-8B79-47E2-8296-23B976558BFA

P6179

Q34424018-C19C0B1C-7679-4375-9770-366CD4F6D3CA

P698

Q34424018-36B0F3C3-8CA8-40F7-A4E4-187DB7CDB15F

P932

Q34424018-EFE3697E-8326-41D4-8F48-0E25DBCB86D8

P356

1471-2407-12-436

P1433

P1476

Evidence for different mechani ...... uired resistant tumour samples

@en

P2093

Alessia Bagnobianchi

http://www.w3.org/2001/XMLSchema#string

Claire Newton

http://www.w3.org/2001/XMLSchema#string

Daniel Hochhauser

http://www.w3.org/2001/XMLSchema#string

Helen L Lowe

http://www.w3.org/2001/XMLSchema#string

John A Hartley

http://www.w3.org/2001/XMLSchema#string

John P Bingham

http://www.w3.org/2001/XMLSchema#string

Jonathan A Ledermann

http://www.w3.org/2001/XMLSchema#string

Konstantinos Kiakos

http://www.w3.org/2001/XMLSchema#string

Victoria J Spanswick

http://www.w3.org/2001/XMLSchema#string

P2860

The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136

The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks

Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma.

Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients.

Repair of DNA interstrand cross-links.

Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay.

Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance.

The resurgence of platinum-based cancer chemotherapy.

Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.

Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors.

P2888

1471-2407-12-436

P304

436

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-12-436

http://www.w3.org/2001/XMLSchema#string

P407

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Charles Craddock

P577

2012-09-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

231610330

http://www.w3.org/2001/XMLSchema#string

P6179

1001410707

http://www.w3.org/2001/XMLSchema#string

P698

23020514

http://www.w3.org/2001/XMLSchema#string

P932

3522549

http://www.w3.org/2001/XMLSchema#string